Timolol — $0 on Listed Strengths

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Glaucoma

• Brimonidine
• Dorzolamide
• Latanoprost

Also listed for Primary Open-Angle Glaucoma

• Brimonidine 0.2% ophthalmic
• Latanoprost 0.005% ophthalmic

Other medications in Ophthalmology

• Travoprost
• Tropicamide
• Verteporfin
• Acetazolamide
• Aflibercept
• Bevacizumab Ophthalmic
• Bimatoprost
• Brinzolamide

About Timolol

Timolol is a widely prescribed medication crucial for managing conditions like glaucoma and ocular hypertension, helping to protect your precious eyesight. For those facing high eye pressure, consistent treatment is key. TheDrugClub understands the importance of affordable access to vital medications, which is why we’re committed to making Timolol accessible and budget-friendly for our members.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Timolol is approved for (FDA label)

Betimol ® is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

Source: Read the full FDA label on DailyMed. Label effective date: June 27, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Timolol (FDA label)

The most frequently reported ocular event in clinical trials was burning/stinging on instillation and was comparable between Betimol ® and timolol maleate (approximately one in eight patients). The following adverse events were associated with use of Betimol ® in frequencies of more than 5% in two controlled, double-masked clinical studies in which 184 patients received 0.25% or 0.5% Betimol ® : OCULAR: Dry eyes, itching, foreign body sensation, discomfort in the eye, eyelid erythema, conjunctival injection, and headache. BODY AS A WHOLE: Headache. The following side effects were reported in frequencies of 1 to 5%: OCULAR: Eye pain, epiphora, photophobia, blurred or abnormal vision, corneal fluorescein staining, keratitis, blepharitis and cataract.

Source: FDA prescribing information (DailyMed). Set ID: 3ae775f4-340c-4bf4-aa49-8a31daba0f8b. SPL document ID: 3891d7f3-d858-9f71-e063-6394a90af95b. Label effective date: June 27, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Timolol (FDA label)

Betimol ® is contraindicated in patients with overt heart failure, cardiogenic shock, sinus bradycardia, second- or third-degree atrioventricular block, bronchial asthma or history of bronchial asthma, or severe chronic obstructive pulmonary disease, or hypersensitivity to any component of this product.

Source: FDA prescribing information (DailyMed). Set ID: 3ae775f4-340c-4bf4-aa49-8a31daba0f8b. SPL document ID: 3891d7f3-d858-9f71-e063-6394a90af95b. Label effective date: June 27, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Timolol (FDA label)

Beta-adrenergic blocking agents Patients who are receiving a beta-adrenergic blocking agent orally and Betimol ® should be observed for a potential additive effect either on the intraocular pressure or on the known systemic effects of beta-blockade. Patients should not usually receive two topical ophthalmic beta-adrenergic blocking agents concurrently. Catecholamine-depleting drugs Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. Calcium antagonists Caution should be used in the co-administration of beta-adrenergic blocking agents and oral or intravenous calcium antagonists, because of possible atrioventricular conduction disturbances, left ventricular failure, and hypotension. In patients with impaired cardiac function, co-administration should be avoided.

Source: FDA prescribing information (DailyMed). Set ID: 3ae775f4-340c-4bf4-aa49-8a31daba0f8b. SPL document ID: 3891d7f3-d858-9f71-e063-6394a90af95b. Label effective date: June 27, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.